SCHEMBL29823683

SCHEMBL29823683

CC(=O)Nc1ccccc1C(=O)N1CCC(N2CCC(N(CCc3ccccn3)Cc3cccc(CNCc4ccccn4)c3)CC2)CC1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CCR3 P51677 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ TP53BP1 Q12888 1/20 0.37
▸ L3MBTL3 Q96JM7 1/20 0.37
▸ MAPT P10636 1/20 0.36
▸ CCR5 P51681 3/20 0.35
▸ KCNH2 Q12809 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ THRB P10828 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ GLA P06280 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ CHRM2 P08172 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1886461 1.00 CCR3 (0.40) CCR3MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3877170 0.83 L3MBTL1 (0.37) CCR3MEN1KMT2AL3MBTL1TP53BP1
SCHEMBL1870607 0.82 CCR3 (0.45) CCR3MEN1KMT2AALDH1A1MAPT
SCHEMBL29823495 0.82 CCR3 (0.45) CCR3MEN1KMT2AALDH1A1MAPT
SCHEMBL29823437 0.75 CCR1 (0.42) CCR3MEN1KMT2AALDH1A1KCNH2
SCHEMBL1879075 0.75 CCR1 (0.42) CCR3MEN1KMT2AALDH1A1KCNH2
SCHEMBL28438648 0.75 CCR1 (0.42) CCR3MEN1KMT2AALDH1A1KCNH2
SCHEMBL5790256 0.74 KMT2A (0.41) CCR3MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL1873995 0.73 KMT2A (0.50) CCR3MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL29823211 0.73 KMT2A (0.50) CCR3MEN1KMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025230907-A1 A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-11-06 — — WO disclosed
EP-4308694-A1 DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS Magenta Therapeutics, Inc. (US) 2024-01-24 — — EP disclosed
EP-4143302-A1 METHODS AND COMPOSITIONS FOR TRANSDUCING HEMATOPOIETIC STEM AND PROGENITOR CELLS IN VIVO Magenta Therapeutics, Inc. (US) 2023-03-08 — — EP disclosed
WO-2022197776-A1 DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS Magenta Therapeutics, Inc. (US) 2022-09-22 — — WO disclosed
EP-4051298-A1 DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENTOR CELLS Magenta Therapeutics, Inc. (US) 2022-09-07 — — EP disclosed
Send feedback